Army Medical Research and Materiel Command
The U.S. Army Medical Research and Materiel Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition and medical logistics management. Its efforts focus on military infectious diseases; combat casualty care; military operational medicine; medical chemical and biological defense; and clinical and rehabilitative medicine.
Virus-like magnetic particles for immunodiagnostics
This VLP conjugated microsphere system will allow more rapid and efficient detection of endemic and emerging viral pathogens in human populations
Core temperature estimation and heat injury prevention app
Field-deployable early warning system of an impending rise in core temperature reduces the incidence of heat injuries
Evolutionarily distinct polynucleotides for calibration and standardization of...
Use of calibrator sequences which are evolutionary unrelated to humans or viruses and microorganisms which infect humans avoids cross-reactivity of primers and probes
Development, test, and quality assurance environment for decision...
Hardware and software system enables the safe and expedient adoption of new patient care procedures
Method for visualizing the performance of frequency lowering...
A simple and user-friendly assessment tool for hearing care professionals
Equine encephalitis virus vaccine
Confers protection against western, eastern and Venezuelan EEV
DNA vaccine for hemorrhagic fever with renal syndrome
Creates neutralizing antibodies against four hantavirus strains
Group B meningitis vaccine
Multivalent vaccine candidate with multiple meningococcal antigens, each with capacity to induce bactericidal antibodies
Filovirus diagnostic kit
Fast, safe, and accurate diagnosis and serological surveillance of infections caused by multiple species of the highly infectious Ebola and Marburg viruses
Molecular Pap and HPV Discover
Two new molecular tools increase the accuracy of HPV diagnosis and indicate disease severity
Novel small molecule inhibits pro-inflammatory response
Promising compound targeting MyD88 limits inflammatory cytokine production in human primary cells and increases therapeutic efficacy in mice with exposure to toxins